| Titolo |
Pubblicato in |
Anno |
| Incorporating immune checkpoint inhibitors in epithelial ovarian cancer |
GYNECOLOGIC ONCOLOGY |
2025 |
| Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study |
GYNECOLOGIC ONCOLOGY |
2025 |
| The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer |
GYNECOLOGIC ONCOLOGY |
2025 |
| Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| External validation of the annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial |
THE LANCET |
2025 |
| Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial |
THE LANCET ONCOLOGY |
2025 |
| The role of molecular classification in endometrial cancer: a focus on patients with low-volume metastasis-a retrospective multi-center study and literature review |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| Evaluation of survival and mortality in pelvic exenteration for gynecologic malignancies: a systematic review, meta-analyses, and meta-regression study |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| Declaration on cervical cancer elimination: literature review and perspectives from early-career clinicians |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| IGCS 2024 Dublin: Highlights of research presented at the annual meeting |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| Rewinding the clock on positive peritoneal cytology in endometrial cancer: does it predict prognosis in low-risk disease? |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2025 |
| Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey |
JOURNAL OF GYNECOLOGIC ONCOLOGY |
2024 |
| Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi) |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2024 |
| Low-Volume Metastases in Apparent Early-Stage Endometrial Cancer: Prevalence, Clinical Significance, and Future Perspectives |
CANCERS |
2024 |
| Cervical cancer: a new era |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2024 |
| Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story |
ANNALS OF ONCOLOGY |
2024 |
| Impact of molecular classification on recurrence risk in endometrial cancer patients with lymph node metastasis: multicenter retrospective study |
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2024 |
| Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer |
ARCHIVES OF GYNECOLOGY AND OBSTETRICS |
2024 |
